E3LΔ83N-TK--hFlt3L

E3LΔ83N-TK--hFlt3L is an engineered oncolytic vaccinia virus (Western Reserve strain) designed for cancer immunotherapy. It features a deletion of the Z-DNA-binding domain of the E3 protein (E3LΔ83N), which attenuates the virus by approximately 1000-fold, and a deletion of the thymidine kinase (TK) gene to enhance tumor selectivity. The virus is further modified to express human FMS-like tyrosine kinase 3 ligand (hFlt3L), a potent cytokine that promotes the expansion and activation of dendritic cells, thereby enhancing antitumor T-cell responses. Developed by researchers at Memorial Sloan Kettering Cancer Center in collaboration with Sound Biologics, this agent is intended for intratumoral delivery to alter the immunosuppressive tumor microenvironment and stimulate systemic immunity against both injected and distant tumors.

Other names

E3LΔ83N-TK-hFlt3Loncolytic vaccinia virus expressing hFlt3L